Diabetes Care:塑化剂同老年人糖尿病有关(PIVUS研究)

2012-04-20 佚名 中国医学论坛报手机报

  瑞典一项研究显示,数种邻苯二甲酸酯(最常用的塑化剂)代谢物与罹患糖尿病、胰岛素分泌和抵抗指标相关。该研究提示,这些常用化学物质在暴露量水平就可能影响老年人葡萄糖代谢。研究于4 月12日在线发表于《糖尿病护理》(Diabetes Care )杂 志。   此项研究纳入乌普萨拉年长者血管系统前瞻性(PIVUS)研究中的1016位70岁老年人,测定四种邻苯二

  瑞典一项研究显示,数种邻苯二甲酸酯(最常用的塑化剂)代谢物与罹患糖尿病、胰岛素分泌和抵抗指标相关。该研究提示,这些常用化学物质在暴露量水平就可能影响老年人葡萄糖代谢。研究于4 月12日在线发表于《糖尿病护理》(Diabetes Care )杂 志。

  此项研究纳入乌普萨拉年长者血管系统前瞻性(PIVUS)研究中的1016位70岁老年人,测定四种邻苯二甲酸酯代谢物。结果显示,114例有糖尿病,校正性别、体质指数、血清胆固醇和甘油三酯水平、教育程度以及吸烟、运动锻炼等因素后,有三种邻苯二甲酸酯代谢物与罹患糖尿病显著相关,其中一种主要与胰岛素分泌减少相关,另外两种主要与胰岛素抵抗相关。

PIVUS相关文献:

Benedict C, Brooks SJ, Kullberg J, Burgos J, Kempton MJ, Nordenskjöld R, Nylander R, Kilander L, Craft S, Larsson EM, Johansson L, Ahlström H, Lind L, Schiöth HB.Impaired insulin sensitivity as indexed by the HOMA score is associated with deficits in verbal fluency and temporal lobe gray matter volume in the elderly. Diabetes Care. 2012 Mar;35(3):488-94

Sandhagen B, Lind L. The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Clin Hemorheol Microcirc. 2012 Jan 3.

Olsén L, Lampa E, Birkholz DA, Lind L, Lind PM. Circulating levels of bisphenol A (BPA) and phthalates in an elderly population in Sweden, based on the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS). Ecotoxicol Environ Saf. 2012 Jan;75(1):242-8.

Jobs E, Ingelsson E, Risérus U, Nerpin E, Jobs M, Sundström J, Basu S, Larsson A, Lind L, Ärnlöv J. Association between serum cathepsin S and mortality in older adults.JAMA. 2011 Sep 14;306(10):1113-21.

Lee DH, Lind PM, Jacobs DR Jr, Salihovic S, van Bavel B, Lind L.Polychlorinated biphenyls and organochlorine pesticides in plasma predict development of type 2 diabetes in the elderly: the prospective investigation of the vasculature in Uppsala Seniors (PIVUS) study.Diabetes Care. 2011 Aug;34(8):1778-84.



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1900942, encodeId=137519009429d, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jul 21 17:13:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759131, encodeId=a6421e591315c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Feb 24 19:13:00 CST 2013, time=2013-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636492, encodeId=cde8163649227, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 29 14:13:00 CST 2012, time=2012-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775134, encodeId=dff31e75134df, content=<a href='/topic/show?id=b6f5422051e' target=_blank style='color:#2F92EE;'>#塑化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42205, encryptionId=b6f5422051e, topicName=塑化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b1738750708, createdName=zzc2224, createdTime=Sat Sep 15 07:13:00 CST 2012, time=2012-09-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1900942, encodeId=137519009429d, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jul 21 17:13:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759131, encodeId=a6421e591315c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Feb 24 19:13:00 CST 2013, time=2013-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636492, encodeId=cde8163649227, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 29 14:13:00 CST 2012, time=2012-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775134, encodeId=dff31e75134df, content=<a href='/topic/show?id=b6f5422051e' target=_blank style='color:#2F92EE;'>#塑化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42205, encryptionId=b6f5422051e, topicName=塑化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b1738750708, createdName=zzc2224, createdTime=Sat Sep 15 07:13:00 CST 2012, time=2012-09-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1900942, encodeId=137519009429d, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jul 21 17:13:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759131, encodeId=a6421e591315c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Feb 24 19:13:00 CST 2013, time=2013-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636492, encodeId=cde8163649227, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 29 14:13:00 CST 2012, time=2012-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775134, encodeId=dff31e75134df, content=<a href='/topic/show?id=b6f5422051e' target=_blank style='color:#2F92EE;'>#塑化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42205, encryptionId=b6f5422051e, topicName=塑化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b1738750708, createdName=zzc2224, createdTime=Sat Sep 15 07:13:00 CST 2012, time=2012-09-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1900942, encodeId=137519009429d, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jul 21 17:13:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759131, encodeId=a6421e591315c, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Feb 24 19:13:00 CST 2013, time=2013-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636492, encodeId=cde8163649227, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 29 14:13:00 CST 2012, time=2012-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775134, encodeId=dff31e75134df, content=<a href='/topic/show?id=b6f5422051e' target=_blank style='color:#2F92EE;'>#塑化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42205, encryptionId=b6f5422051e, topicName=塑化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b1738750708, createdName=zzc2224, createdTime=Sat Sep 15 07:13:00 CST 2012, time=2012-09-15, status=1, ipAttribution=)]
    2012-09-15 zzc2224